Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus (DISC)
2016年1月12日 更新者:Demao Yang、B & Y Technologies
Pilot Study of a Cell-Based Therapy for Treatment of Hyperglycemia in Type 2 Diabetes Mellitus
Diabetes mellitus type 2 is a long-term metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency and hyperglycemia.
Our hypotheses is that liver would be the primary organ responsible for the metabolic disorder because of some unknown defects, where sugar would not be efficiently converted to glycogen and fat, leading to hyperglycemia.
The constant hyperglycemia would keep pressure on beta-cells in the pancreas to eventually exhaust their ability to produce and secret sufficient amount of insulin, exacerbating the disease.
The Immunotherapy would enhance the liver functions and correct the abnormal sugar metabolism.
In addition, the ex vivo activated cells produce and secret growth factors which would help endothelial cells of blood vessels to reproduce and grow, resulting in reduced arteriosclerosis.
研究概览
详细说明
We plan to recruit 20 patients with type 2 diabetes mellitus who suffer hyperglycemia with or without medication.
The patients will come to our hospitals for the treatment.
A small amount of peripheral blood will be drawn and processed and cultured in our laboratory.
The cultured cells (autologous) will be infused intravenously back to patients.
Levels of plasma hemoglobin A1c (HbA1c) and other metabolic parameters before and after the therapy will be compared.
The therapy is planned to take four weeks for each patient.
研究类型
介入性
注册 (实际的)
25
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510620
- The 12th People's Hospital of Guangzhou
-
Shenzhen、Guangdong、中国、518001
- The 12th People's Hospital of Shenzhen
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
25年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- 1. Patients diagnosed with type 2 diabetes mellitus.
- 2. 25 years of age or older. Both sexes.
- 3. HbA1c ≧6.5% for more than 6 months with or without medication.
- 4. Capability of providing informed consent.
Exclusion Criteria:
- 1. History of malignancy.
- 2. Patients with active infections.
- 3. Seropositivity for HIV infection.
- 4. History of myocardial infarction or unstable angina in the previous 3 months.
- 5. Pregnancy or nursing.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:ex vivo activated immune cells
Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group.
Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory.
The ex vivo activated autologous blood cells will be infused intravenously back to patients.
The treatment will be done twice a week for consecutive 4 weeks.
The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
|
The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment.
The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Change from Baseline Hemoglobin A1c (HbA1c) at up to 27 weeks.
大体时间:Point 1: The week (week 1) before the first cell infusion assessed as the baseline; Point 2: The week (week 6) after the last cell infusion; Point 3 and after: every 4 weeks up to 27 weeks.
|
Point 1: The week (week 1) before the first cell infusion assessed as the baseline; Point 2: The week (week 6) after the last cell infusion; Point 3 and after: every 4 weeks up to 27 weeks.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change from Baseline Lipid Profile at up to 27 weeks.
大体时间:Point 1: The week (week 1) before the first cell infusion assessed as the baseline; Point 2: The week (week 6) after the last cell infusion; Point 3 and after: every 4 weeks up to 27 weeks.
|
Lipid profile includes cholesterol, triglycerides, HDL cholesterol and LDL cholesterol.
|
Point 1: The week (week 1) before the first cell infusion assessed as the baseline; Point 2: The week (week 6) after the last cell infusion; Point 3 and after: every 4 weeks up to 27 weeks.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change from Baseline Symptoms at up to 27 weeks.
大体时间:Point 1: The week (week 1) before the first cell infusion assessed as the baseline; Point 2: The week (week 6) after the last cell infusion; Point 3 and after: every 4 weeks up to 27 weeks.
|
The symptoms include insomnia, anorexia, fatigue, frequent trips to the bathroom, unquenchable thirst and blurred vision.
|
Point 1: The week (week 1) before the first cell infusion assessed as the baseline; Point 2: The week (week 6) after the last cell infusion; Point 3 and after: every 4 weeks up to 27 weeks.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Lingzhen Chen, MD、The 12th People's Hospital of Guangzhou.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2014年3月1日
初级完成 (实际的)
2015年6月1日
研究完成 (实际的)
2016年1月1日
研究注册日期
首次提交
2014年6月17日
首先提交符合 QC 标准的
2014年6月20日
首次发布 (估计)
2014年6月23日
研究记录更新
最后更新发布 (估计)
2016年1月13日
上次提交的符合 QC 标准的更新
2016年1月12日
最后验证
2016年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.